| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.26 | 3e-07 |
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.23 | 3e-06 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.15 | 9e-06 |
| mRNA | TKI258 | CCLE | pan-cancer | AAC | -0.23 | 1e-05 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.18 | 2e-05 |
| mRNA | AZ628 | GDSC1000 | pan-cancer | AAC | -0.22 | 3e-05 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.13 | 0.0001 |
| mRNA | KW-2449 | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0002 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | austocystin d | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0003 |